Targeted Antibody-Drug could shrink Hard-to-Treat ovarian cancers
Disease control
Not yet recruiting
This trial tests a drug called sacituzumab govitecan in people with advanced or recurrent ovarian, fallopian tube, or primary peritoneal cancer that has high levels of a protein called TROP-2. Participants must have already tried standard treatments without success. The drug is g…
Phase: PHASE1 • Sponsor: Shanghai Gynecologic Oncology Group • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC